Biomedical subjects

Masato Sakon

Publications and source records attributed to Masato Sakon.

96 records · Page 6Linked to original sources

PubMed2002

[A case of postoperative multiple hepatic metastasis from gastric cancer successfully treated by percutaneous microwave coagulation therapy and hepatic arterial infusion chemotherapy].

A 61-year-old male who underwent radical resection for gastric cancer was diagnosed with multiple hepatic metastasis 2 years and 2 months after the surgery. He first underwent percutaneous microwave hepatic coagulation therapy with segmental hepatic blood flow occlusion and obtained complete coagulation of the main tumor. Consecutively, he received hepatic arterial infusion chemotherapy (FAP: 5-FU, cisplatin, adriamycin) against residual multiple hepatic tumors. These hepatic recurrent lesions disappeared completely after 3 sessions of arterial infusion chemotherapy. At present, this patient is alive with no recurrent lesions, 1 year and 6 months from the beginning of treatment for hepatic metastasis. Recently, we tried hepatic arterial infusion chemotherapy (FAP) in four cases in which the recurrence from gastric cancer was not only in the liver but elsewhere. The response rate (CR and PR) was 75% and no major side effects were observed. In conclusion, some cases can obtain longer survival if the multimoderate therapy including hepatic arterial infusion chemotherapy (FAP) and microwave coagulation therapy are effective.

Aged↗

PubMedDate not supplied

Ets-2 overexpression contributes to progression of pancreatic adenocarcinoma.

Ets-2, a transcriptional factor, has been linked to carcinoma progression but in-depth studies on its expression in human carcinoma have not been done. The present study investigated ets-2 expression in pancreatic adenocarcinoma. The ets-2 labeling index (LI) in normal pancreatic duct and pancreatic adenocarcinoma averaged 33.1+/-8.4 and 43.1+/-18.6, respectively. No statistical significance was found between the LI of normal duct and that of carcinoma with low biological aggressiveness. However, in cases with highly aggressive phenotypes such as stage IV, moderate or poor differentiation, lymph node metastasis, larger size, vascular invasion, lymphatic invasion, perineural invasion, retropancreatic invasion and capsular invasion, the ets-2 LI was significantly higher than in normal ducts and in cases with lower biological aggressiveness. Also, ets-2 transfected pancreatic carcinoma cells, when injected into athymic mice caused the formation of large tumors. These results suggest that ets-2 plays a role in the progression of pancreatic adenocarcinoma predominantly in the late phase.

Adenocarcinoma↗

PubMedDate not supplied

Linkage of elevated ets-2 expression to hepatocarcinogenesis.

BACKGROUND: Previous studies have shown that ets-2, a transcription factor, is linked to carcinoma progression. In the present study, we investigated the expression and clinical significance of ets-2 in hepatocellular carcinoma (HCC) and malignant transformation of the liver. MATERIALS AND METHODS: The expression of ets-2 was immunohistochemically investigated with 91 HCC, 46 noncancerous lesions, 8 atypical adenomatous hyperplasias and 14 normal liver controls. RESULTS: The ets-2 labeling index (LI) in normal liver was significantly lower than in noncancerous lesion (p<0.0001). The LI in atypical adenomatous hyperplasia tended to be higher than in noncancerous lesion (p=.0779). In HCC, the LI was significantly lower (p<0.0001) than that in noncancerous lesion and atypical adenomatous hyperplasia. In HCC, the ets-2 expression level was significantly lower in cases with advanced stage (p=0.0085), large size (p=0.0441), high proliferating activity (p<0.0001), poor differentiation (p=0.0005), the presence of portal invasion (p=0.0009) and intrahepatic metastasis (p=0.0236) and shorter disease-free survival (p=0.0372). CONCLUSION: These findings suggest that ets-2 plays an important role predominantly in malignant transformation of the liver.

Carcinoma, Hepatocellular↗

PubMedDate not supplied

Adenosquamous carcinoma of the gallbladder.

BACKGROUND/AIMS: Adenosquamous carcinoma of the gallbladder is relatively rare. Its biological behavior and optimal surgical procedure are still controversial. METHODOLOGY: Clinicopathological factors and proliferating cell nuclear antigen expression were studied in four stage IV adenosquamous carcinoma patients who underwent curative surgery between June 1987 and April 2000, comparing those of 14 stage IV adenocarcinoma patients at the same period. RESULTS: Preoperative radiological evaluation disclosed a mass invading to the adjacent organs in all cases (liver in 3 cases, and liver and stomach in one case). Three patients (case 1, 2 and 3: well-differentiated adenosquamous carcinomas) were all alive without recurrence in 10, 7, and 2 years after surgery. In contrast, the remaining patient (case 4: moderately differentiated adenosquamous carcinoma) with positive pathologic factors (lymph node metastasis, vascular invasion, etc) deceased one year after surgery due to peritoneal dissemination. When survival rate of adenosquamous carcinoma was compared, the prognosis of adenosquamous carcinoma was significantly better than that of adenocarcinoma (P = 0.0103). Comparison of pathological factors revealed that the frequency of lymph node metastasis was significantly higher in adenocarcinoma than in adenosquamous carcinoma (P = 0.004). Consistent with these findings, the positivity rate of proliferating cell nuclear antigen labeling was significantly lower in squamous carcinoma component, compared with adenosquamous component (P < 0.0001) or adenocarcinoma (P < 0.0001). CONCLUSIONS: Even in patients with stage IV adenosquamous carcinoma of the gallbladder, a long-term survival may be obtained by curative surgery if the squamous component is predominant.

Aged↗

PubMedDate not supplied

The effect of beta-blocker on intractable ascites in cirrhotic patients undergoing hepatectomy for hepatocellular carcinoma.

BACKGROUND/AIMS: Intractable ascites is one of the serious complications after hepatectomy. Only little is known about their effect on postoperative ascites in patients with liver cirrhosis although beta-blockers have been used for cirrhotic complications including ascites. METHODOLOGY: Here, we report five cases of intractable ascites after hepatectomy, which were treated by propranolol (1 mg/kg/body). RESULTS: In three patients, plasma renin activity and aldosterone concentrations were markedly increased before propranolol administration, but fell to normal levels thereafter. Ascites subsided in all subjects except one, who developed cardiac dysfunction. CONCLUSIONS: Beta-blockers might be a promising drug for intractable ascites in cirrhotic patients undergoing hepatectomy.

Aged↗

PubMedDate not supplied

Efficacy of multi-slice helical CT venography for the diagnosis of deep venous thrombosis: comparison with venous sonography.

OBJECTIVE: The purpose of this study was to assess the efficacy of contrast enhanced multi-slice helical CT (MSCT) venography for the diagnosis of deep venous thrombosis (DVT) in comparison with venous sonography. MATERIALS AND METHODS: MSCT was used to obtain contiguous, 5-mm thick axial CT images from the diaphragm to the ankles of 27 patients after intravenous injection of contrast material. These patients were clinically suspected of having DVT. The same patients underwent venous sonography before CT examination. The detectability of DVT with MSCT venography was compared with that with venous sonography. RESULTS: MSCT venography detected DVT in 21 patients, but venous sonography did so in only 17. MSCT venography detected DVT missed by venous sonography in five patients, while venous sonography detected DVT missed by MSCT venography in one patient. CONCLUSION: MSCT venography can be expected to make a valuable contribution to the diagnosis of DVT and to the prophylaxis of pulmonary embolism.

Contrast Media↗